Table 1.

Studies on Statins and Rhabdomyolysis Included in This Review

References	Study Design	Number of Patients	Treatment	Rhabdomyolysis
Pedersen et al17	RCT	8888	Simvastatin (20 mg/day)	0.07%
			Atorvastatin (80 mg/day)	0.05%
Enger et al20	RCT	584,784	Statin**	0.003%
			Statin** + Fenofibrate*	0.015%
			Statin** + Gemfibrozil*	0.207%
HPS2-THRIVE13	RCT	25,673	Simvastatin (40 mg/day) + ER niacin (2 g/day) and laropiprant (40 mg/day)	0.109%
			Simvastatin (40 mg/day)	0.114%
Cziraky et al21	RCT	473,343	Atorvastatin*	0.0057%
			Pravastatin*	0.010%
			Simvastatin*	0.0055%
			Lovastatin*	0.0038%
			Fluvastatin*	0.016%
			Rosuvastatin*	0.012%
			Cerivastatin*	0.085%
Abraldes et al14	RCT	147	Simvastatin (20 mg/day) (first 15 days) followed by simvastatin (40 mg/day) thereafter	2.9%
Giugliano et al11	RCT	15,281	Simvastatin (40 mg) + ezetimibe (10 mg/day)	0.137%
Berwanger et al10	RCT	4191	Loading doses of atorvastatin (80 mg/day), followed by atorvastatin (40 mg/day)	0.142%
Wierzbicki et al15	Clinical Trial	22	Simvastatin (80 mg/day)	0%
			Simvastatin (120 mg/day)	4.5%
Shepherd et al18	Clinical Trial	16,876	Rosuvastatin (5–40 mg/day)	0.047%
Drobny et al19	Clinical Trial	198	Rosuvastatin*	3.03%
			Fluvastatin*
Goss et al12	Clinical Trial phase 1	24	Rosuvastatin (1–8 mg/kg/day) + erlotinib (150 mg/day)	4.167%
Pose et al16	Clinical trial phase 2	50	Simvastatin (40 mg/day) + rifaximin (1200 mg/day)	19%
			Simvastatin (20 mg/day) + rifaximin (1200 mg/day)	0%

Notes: *Dose is not available; **Dose and type of drug are not available.

Abbreviation: RCT, randomized controlled trial.